Ecto-NTPDase-Inhibitors – Inhibitors for use in human therapy
The invention provides a new class of nucleosides
exhibiting a high affinity for individual ecto-nucleotidetriphosphate- diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors). Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Parallel Paths: Understanding Malaria Resistance in Chimpanzees and Humans
The closest relatives of humans adapt genetically to habitats and infections Survival of the Fittest: Genetic Adaptations Uncovered in Chimpanzees Görlitz, 10.01.2025. Chimpanzees have genetic adaptations that help them survive…
You are What You Eat—Stanford Study Links Fiber to Anti-Cancer Gene Modulation
The Fiber Gap: A Growing Concern in American Diets Fiber is well known to be an important part of a healthy diet, yet less than 10% of Americans eat the minimum recommended…
Trust Your Gut—RNA-Protein Discovery for Better Immunity
HIRI researchers uncover control mechanisms of polysaccharide utilization in Bacteroides thetaiotaomicron. Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a…